



Imagion Biosystems announces new Director

- **Experienced life sciences executive Ms Bronwyn Le Grice appointed Director**
- **Retirement of Mr Peter Di Chiara as Director**

MELBOURNE — April 26, 2018 – Imagion Biosystems Limited (ASX:IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to update shareholders with the following changes to its Board of Directors.

Appointment of Bronwyn Le Grice as Director

Effective 26 April 2018 Ms Bronwyn Le Grice has been appointed as a Non-Executive Director. Ms Le Grice has more than 15 years of experience in healthcare and technology markets spanning venture capital, capital raising and corporate governance for Australian listed companies and non-profit organisations. She is currently Managing Director of ANDHealth, a unique industry-led non-profit organisation focused on strengthening the Australian digital health ecosystem and de-risking innovations in digital health.

Prior to founding ANDHealth, Ms Le Grice was an Investment Director with leading Australian healthcare venture capital firm BioScience Managers, where she was responsible for managing significant transactions in the health technology and digital health sectors, resulting in more than A\$65m of private and public equity raisings. This included IPOs on the Australian Securities Exchange and the UK Alternative Investments Market, in addition to participating in deal origination, due diligence and negotiation for two funds totaling A\$96m under management.

“We are delighted that Bronwyn will be joining our Board,” said Bob Proulx, Executive Chairman of Imagion Biosystems. “With her experience in Australian capital markets, Bronwyn will significantly complement our Board, which is already incredibly strong with real expertise in healthcare markets and professional experience in corporate governance.”

Retirement of Director Peter Di Chiara

Ms Le Grice will replace Peter Di Chiara on the Board, who will retire as a Non-Executive Director of Imagion Biosystems effective 26 April 2018. Mr Di Chiara played a valuable role in helping the Company through its IPO process, and will continue to lend his expertise to the Board on an advisory basis. The Board takes this opportunity to thank Mr Di Chiara for his contribution to the Company.

Update on pending appointment of John Hazle as Director

As noted in the Company’s IPO prospectus, the formal appointment of Dr John Hazle (Professor and Chair of the Department of Imaging Physics at The University of Texas MD Anderson Cancer Center) as Director remains subject to approval from MD Anderson Cancer Center’s Conflict of Interest Committee. The Company expects to receive this approval shortly, and will provide an update to shareholders as and when appropriate.



About Imagion Biosystems

Imagion Biosystems is at the crossroads of biotechnology and nanotechnology. Its novel bioimaging and nanomagnetic detection systems have been developed specifically to detect cancer and other diseases earlier and with higher specificity than is currently possible. With MagSense™ technology, the company has the potential to optimize patient care and reduce mortality rates across various cancer indications. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

Australian Media & Investor Relations:

Matt Wright, NWR Communications
matt@nwrcommunications.com.au
+61-451-896-420

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630